Organization | Laboratorios Ordesa

Laboratorios Ordesa Report issue

For profit Phase 4

Founded: Barcelona Spain (1943)

Status: No NME R&D (1943)

Organization Overview

First Clinical Trial

2011

NCT02096302

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Laboratorios Ordesa

Active Ingredients

Drugs in Phase 4 Trials (7)

autologous microbiome (1 trial)

bifidobacterium longum (1 trial)

boric acid (1 trial)

clindamycin (cleocin) (1 trial)

icosapent ethyl (vascepa) (1 trial)

medium chain triglyceride (1 trial)

Drugs in Other Trials (5)

fiber (1 trial)

guar gum (1 trial)

inulin (1 trial)

maltodextrin (2 trials)

prunus domestica (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Attention Deficit Disorder with Hyperactivity (Phase 4)

Candidiasis (Phase 4)

Digestive System Diseases (Phase 4)

Gastrointestinal Diseases (Phase 4)

Hyperkinesis (Phase 4)

Vaginal Diseases (Phase 4)

Vaginosis, Bacterial (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial APIs: 12